OncoTricks

Cervical cancer staging and KEYNOTE-A18, Oct 29, 2026

Cervical cancer: FIGO 2018 or 2014?

Two women with cervical cancer, both written as "stage III". One has a 3 cm tumor with pelvic nodes on PET. The other has a tumor reaching the pelvic wall and no nodes. Pembrolizumab with chemoradiation is on the table for both. Are they the same stage?

If you remember one thingFIGO 2018 puts any positive node in stage IIIC, unless the disease is already stage IV. FIGO 2014 ignores nodes, and KEYNOTE-A18 and its FDA label were written in FIGO 2014. Always ask: which FIGO?

Concepts first

FIGO
International Federation of Gynecology and Obstetrics, which writes the cervical cancer staging. FIGO 2018 is still current (confirmed in the 2025 FIGO report).
FIGO 2014
The prior system, the same cervix rules as FIGO 2009 (approved in 2008). Trials designed before 2019 kept it: KEYNOTE-A18 enrolled 2020 to 2022 in FIGO 2014. It stages by exam and does not count lymph nodes.
r and p
In FIGO 2018, nodes found on imaging are IIIC "r"; nodes proven on pathology are IIIC "p". Isolated tumor cells do not change the stage.
Parametrium
The connective tissue beside the cervix, between it and the pelvic wall.
LVSI
Lymphovascular space invasion: tumor in small vessels on the biopsy. Prognostic, but it never changes the stage.
STAGE I: TWO MICROSCOPE CUTS, TWO RULER CUTSIA1invasion 3 mm or less deepIA2over 3 mm, up to 5 mm deepIB1over 5 mm deep, up to 2 cmIB2over 2 cm, up to 4 cmIB3over 4 cmConfined to the cervix. LVSI never changes the stage.
BEYOND THE CERVIX: WHERE IT WENTIIAupper two thirds of the vaginaIIA1 4 cm or less, IIA2 over 4 cmIIBparametrium, not to the pelvic wallIIIAlower third of the vaginaIIIBpelvic wall, or hydronephrosisor a nonfunctioning kidneyIIIC1pelvic nodesany T; add r (imaging) or p (pathology)IIIC2para-aortic nodesany T; r or pIVAbladder or rectal mucosa, biopsy provenbullous edema alone does not countIVBdistant organs

How FIGO 2018 assigns the stage.Exam first, then any imaging or pathology available. Pathology overrides imaging and exam. When in doubt, choose the lower stage. The stage is fixed once all results are in, and is not changed at recurrence (Bhatla 2019; 2025 update).

Why the year matters

SAME PATIENT, TWO RULEBOOKS20182014A18 / label3 cm + nodesIIIC1IB1no / no5 cm + nodesIIIC1IB2yes / noparametrium + nodesIIIC1IIByes / nopelvic wall, N0IIIBIIIByes / yesFIGO 2014 ignores nodes. KEYNOTE-A18 enrolled by FIGO 2014;the FDA label covers FIGO 2014 III to IVA only.

The trap: IIIC in 2018 is not stage III in 2014.A visible tumor of 4 cm or less confined to the cervix, with pelvic nodes, is FIGO 2018 IIIC1 but FIGO 2014 IB1. KEYNOTE-A18 enrolled FIGO 2014 IB2 to IIB with positive nodes, or III to IVA with any nodes, so that patient was not eligible. Same label, different tumor: FIGO 2014 IB2 is over 4 cm (today's IB3); FIGO 2018 IB2 is 2 to 4 cm. A 3 cm tumor charted as "IB2" was not eligible.

Staging in four questions

1. Distant metastasis, or biopsy-proven bladder or rectal mucosa?
yes
IVB (distant) or IVA (mucosa)
no
2. Any positive pelvic or para-aortic node?
yes
IIIC1 (pelvic) or IIIC2 (para-aortic), with r or pFIGO 2014: ignore the nodes and keep asking.
no
3. Lower third of the vagina, pelvic wall, or hydronephrosis?
yes
IIIA (vagina) or IIIB (wall, kidney)
no
4. Beyond the cervix into the parametrium or upper vagina?
yes
IIB (parametrium) or IIA (upper vagina)
no
Stage I by depth and size: IA1, IA2, IB1, IB2, IB3

Try it: stage calculator

Starts on a 3 cm tumor with pelvic nodes on PET. Change any box.

FIGO 2018 and FIGO 2014 for carcinoma of the cervix. FIGO 2014 stage IA also required horizontal spread of 7 mm or less; the calculator assumes it. The trial line uses KEYNOTE-A18 entry stages and the FDA label; performance status and other entry criteria still apply. The trial excluded nodes above L1 or in the groin, and bilateral hydronephrosis unless drained.

Memory hooks

Tap a card to flip it.

Check yourself

Question 14 mm deep invasion on a cone, margins clear, no visible lesion, PET negative. Stage?

IA2 (over 3 to 5 mm). LVSI on the cone would not change it.

Question 23 cm tumor confined to the cervix; PET shows two avid external iliac nodes, not biopsied. FIGO 2018 and FIGO 2014?

FIGO 2018 IIIC1r. FIGO 2014 IB1, because 2014 ignores nodes. Not eligible for KEYNOTE-A18 and outside the pembrolizumab label.

Question 36 cm tumor into the parametrium, hydronephrosis on the right, no nodes. Stage?

IIIB in both systems: the blocked kidney wins over the parametrium. Inside KEYNOTE-A18 and on the FDA label.

Question 4Cystoscopy shows bullous edema of the bladder; biopsy negative. Tumor 5 cm with parametrial invasion, no nodes. IVA?

No. Bullous edema alone is not IVA. FIGO 2018 IIB, FIGO 2014 IIB. Without nodes, outside KEYNOTE-A18.

Question 5Same IIB patient, but PET shows a para-aortic node, biopsy positive.

FIGO 2018 IIIC2p. FIGO 2014 still IIB, now node positive: inside the KEYNOTE-A18 entry stages if the node is no higher than L1, outside the label. Para-aortic disease also changes the radiation field.

Sources

Retrieved from PubMed and FDA communications, read on Oct 30, 2026.

  1. Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145:129-135. doi:10.1002/ijgo.12749
  2. Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2025 update. Int J Gynaecol Obstet 2025;171 Suppl 1:87-108. doi:10.1002/ijgo.70277
  3. Corrigendum to "Revised FIGO staging for carcinoma of the cervix uteri". Int J Gynaecol Obstet 2019;147:279-280 (source of the cut-point wording). doi:10.1002/ijgo.12969
  4. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-104. doi:10.1016/j.ijgo.2009.02.012
  5. FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 2014;125:97-98. doi:10.1016/j.ijgo.2014.02.003
  6. Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 2024;403:1341-1350. doi:10.1016/S0140-6736(24)00317-9